# A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

> **NCT05375838** · PHASE1,PHASE2 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 550 (actual)

## Conditions studied

- SARS-CoV-2
- Influenza

## Interventions

- **BIOLOGICAL:** mRNA-1073
- **BIOLOGICAL:** mRNA-1010
- **BIOLOGICAL:** mRNA-1273
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05375838
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-13
- **Primary completion:** 2022-12-29
- **Final completion:** 2022-12-29
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05375838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05375838, "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05375838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*